On 6 February, CHC Group Ltd. (NYSE:HELI), announced that the board of directors has appointed Karl Fessenden chief executive officer and a member of the board of directors effective Feb. 9, replacing William Amelio, who will be leaving the company. Mr. Fessenden joins CHC from GE, where over his 20-year career at the company he successfully led multiple global service business units, at GE Energy and GE Aviation. On Wednesday shares of CHC Group Ltd. (NYSE:HELI) closed at $2.09. Company’s sales growth for last 5 years was 18.30% and EPS growth for next 5 years is recorded as 12.00%.
On 3 February, Sanofi and MannKind Corporation (NASDAQ:MNKD) announced that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corp. (NASDAQ:MNKD) in last trading activity decreased -2.11% to close at $7.42. Company weekly performance is 9.04% while its quarterly performance stands at 26.19%. MannKind Corp. (NASDAQ:MNKD) is -35.37% away from its 52 week high.
American Water Works Company, Inc. (NYSE:AWK) announced that it intends to release its 2014 fourth quarter and year-end financial results after the market closes on Tuesday, Feb. 24, 2015.On last trading day American Water Works Company, Inc. (NYSE:AWK) decreased -1.40% to close at $53.54. Its volatility for the week is 2.13% while volatility for the month is 1.81%. AWK’s sales growth for past 5 years was 4.40% and its EPS growth for past 5 years was 20.90%. American Water Works Company, Inc. (NYSE:AWK) monthly performance is -0.54%.
Smith & Wesson Holding Corporation (NASDAQ:SWHC) will host a conference call and webcast on March 3, 2015, to discuss its third quarter fiscal 2015 financial and operational results. Smith & Wesson Holding Corporation (NASDAQ:SWHC) has 1.80% insider ownership while its institutional ownership stands at 67.70%. In last trading activity company’s stock closed at $12.50.
Novartis A.G. (NYSE:NVS) recently announced that its ophthalmology unit Alcon has received FDA approval for the ophthalmic solution Pazeo (olopatadine hydrochloride solution) 0.7% for the treatment of ocular itching associated with allergic conjunctivitis. On last trading day Novartis AG (NYSE:NVS) increased 0.01% to close at $102.28. Its volatility for the week is 1.12% while volatility for the month is 1.54%. NVS’s sales growth for past 5 years was 3.50% and its EPS growth for past 5 years was 3.20%. Novartis AG (NYSE:NVS) monthly performance is 7.12%.